View in EDS

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.

Saved in:
Bibliographic Details
Title: Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Authors: Johnson ML; Department of Medical Oncology, Sarah Cannon Cancer Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee. Electronic address: Melissa.Johnson@sarahcannon.com., Zvirbule Z; Latvian Oncology Centre, Riga East University Hospital, Riga, Latvia., Laktionov K; Federal State Budgetary Institution 'N.N.Blokhin National Medical Research Center of Oncology' of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia., Helland A; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Gutierrez V; Department of Medical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain., Colinet B; Department of Pneumology, Grand Hôpital de Charleroi, Charleroi, Belgium., Lena H; Centre Hospitalier Universitaire, Rennes, Hospital de Pontchaillou, France; INSERM U 1242, Université Rennes 1, Rennes, France., Wolf M; Department of Hematology and Oncology, Klinikum Kassel Hospital, Kassel, Germany., Gottfried M; Department of Oncology, Meir Medical Center, Kfar Saba, Israel., Okamoto I; Department of Medical Oncology, Kyushu University Hospital, Fukuoka, Japan., van der Leest C; Department of Pulmonology, Amphia Ziekenhuis, Breda, the Netherlands., Rich P; Department of Medical Oncology, Cancer Treatment Centers of America, Newnan, Georgia., Hung JY; Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan., Appenzeller C; Division of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Sun Z; AbbVie, Inc, North Chicago, Illinois., Maag D; AbbVie, Inc, North Chicago, Illinois., Luo Y; AbbVie, Inc, North Chicago, Illinois., Nickner C; AbbVie, Inc, North Chicago, Illinois., Vajikova A; AbbVie, Inc, North Chicago, Illinois., Komarnitsky P; AbbVie, Inc, North Chicago, Illinois., Bar J; Department of Oncology, Sheba Medical Center, Ramat Gan, Israel; Sackler Medical School, Tel-Aviv University, Tel-Aviv, Israel.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Sep; Vol. 16 (9), pp. 1570-1581. Date of Electronic Publication: 2021 Apr 03.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1556-1380
DOI:10.1016/j.jtho.2021.03.012